Roberto Labianca
666 works · 41,797 citations · h-index 86
Top works
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- Randomized Controlled Trial
- Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials
- A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
- Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
- Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer
- Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials
- A New Palliative Prognostic Score
- Successful Validation of the Palliative Prognostic Score in Terminally Ill Cancer Patients
- Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies
- Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
- Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up